Paul M. Harari
#136,630
Most Influential Person Now
Paul M. Harari's AcademicInfluence.com Rankings
Paul M. Harariphilosophy Degrees
Philosophy
#6933
World Rank
#10059
Historical Rank
Logic
#4015
World Rank
#5256
Historical Rank
Download Badge
Philosophy
Why Is Paul M. Harari Influential?
(Suggest an Edit or Addition)Paul M. Harari's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. (2006) (4805)
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. (2010) (1824)
- Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. (1999) (739)
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial (2019) (716)
- Understanding resistance to EGFR inhibitors—impact on future treatment strategies (2010) (613)
- Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. (2000) (597)
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members (2008) (535)
- Image guidance for precise conformal radiotherapy. (2003) (491)
- Epidermal growth factor receptor inhibition strategies in oncology. (2004) (409)
- Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). (2005) (389)
- Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR) (2004) (388)
- Enhanced radiation sensitivity in HPV-positive head and neck cancer. (2013) (332)
- Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). (2010) (304)
- p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. (2014) (300)
- Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). (2002) (281)
- The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. (2005) (277)
- Modulation of radiation response by histone deacetylase inhibition. (2005) (249)
- Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. (2004) (237)
- Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. (2007) (229)
- Epidermal Growth Factor Receptor Inhibition in Cancer Therapy: Biology, Rationale and Preliminary Clinical Results (2004) (224)
- Oral tongue cancer in young adults less than 40 years of age: Rationale for aggressive therapy (1994) (220)
- Biology of interactions: antiepidermal growth factor receptor agents. (2007) (220)
- Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. (2001) (196)
- Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. (2016) (178)
- Biologic basis for combining drugs with radiation. (2006) (176)
- Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. (2013) (163)
- IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer (2001) (163)
- Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. (2014) (160)
- Helical Tomotherapy: An Innovative Technology and Approach to Radiation Therapy (2002) (158)
- Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma (2010) (155)
- Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab (2009) (150)
- Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement (2020) (143)
- Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. (2002) (142)
- Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions (2007) (137)
- Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. (2003) (125)
- Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. (2013) (124)
- p53 modulates acquired resistance to EGFR inhibitors and radiation. (2011) (116)
- Heterogeneity in head and neck IMRT target design and clinical practice. (2012) (114)
- Parotidectomy: Ten-Year Review of 237 Cases at a Single Institution (2007) (110)
- Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. (2001) (107)
- Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? (1997) (105)
- Planned postradiotherapy neck dissection in patients with advanced head and neck cancer (1998) (104)
- In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. (2016) (102)
- Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells (2009) (100)
- Modulation of molecular targets to enhance radiation. (2000) (100)
- Insulin-like growth factor-I receptor signaling blockade combined with radiation. (2007) (95)
- A comprehensive assessment by tumor site of patient setup using daily MVCT imaging from more than 3,800 helical tomotherapy treatments. (2009) (92)
- A Multi-Institutional Experience of MR-Guided Liver Stereotactic Body Radiation Therapy (2018) (91)
- Merkel cell carcinoma. Improved locoregional control with postoperative radiation therapy (1991) (90)
- The role of radiotherapy in the treatment of malignant sweat gland neoplasms (1990) (90)
- Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts (2012) (87)
- Clinical Implementation of Adaptive Helical Tomotherapy: A Unique Approach to Image-Guided Intensity Modulated Radiotherapy (2006) (86)
- Interaction of radiation therapy with molecular targeted agents. (2014) (85)
- Radiation combined with EGFR signal inhibitors: head and neck cancer focus. (2006) (81)
- Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results? (2004) (78)
- Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) (2016) (77)
- Emphasizing conformal avoidance versus target definition for IMRT planning in head-and-neck cancer. (2010) (76)
- Impact of conventional radiotherapy on health-related quality of life and critical functions of the head and neck. (2006) (76)
- Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. (2018) (76)
- Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: The University of Wisconsin experience (2009) (75)
- Head and neck squamous cell carcinoma from an unknown primary site. (2011) (75)
- Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. (2005) (75)
- Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison. (2007) (72)
- Intensity-modulated radiation therapy: emerging cancer treatment technology (2005) (71)
- Development of scanned focussed ultrasound hyperthermia: clinical response evaluation. (1991) (68)
- Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. (2009) (68)
- Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234) (2016) (63)
- Enhancement of radiation response with bevacizumab (2012) (63)
- Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. (2015) (63)
- The Promise of Combining Radiation Therapy with Immunotherapy. (2020) (60)
- Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement (2020) (57)
- Longitudinal oncology registry of head and neck carcinoma (LORHAN) (2011) (57)
- Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012. (2016) (53)
- Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition (2006) (53)
- Pterygium treated with excision and postoperative beta irradiation. (1992) (53)
- Variations in target delineation for head and neck IMRT: An international multi-institutional study (2004) (52)
- Small cell carcinoma of the head and neck: An analysis of the National Cancer Database. (2017) (52)
- EGFR-targeting monoclonal antibodies in head and neck cancer. (2006) (51)
- Gadoxetate for direct tumor therapy and tracking with real-time MRI-guided stereotactic body radiation therapy of the liver. (2016) (51)
- Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites (2018) (51)
- A New Era of Image Guidance with Magnetic Resonance-guided Radiation Therapy for Abdominal and Thoracic Malignancies (2018) (51)
- Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development. (2002) (50)
- Radiation‐Induced Angiosarcoma of the Breast: Case Report and Review of the Literature (1994) (50)
- Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. (2006) (50)
- Promising new advances in head and neck radiotherapy. (2005) (50)
- Planned Postradiotherapy Neck Dissection: Rationale and Clinical Outcomes (2007) (48)
- Human organotypic lymphatic vessel model elucidates microenvironment-dependent signaling and barrier function. (2019) (45)
- Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients. (2019) (44)
- Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy (2014) (43)
- Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. (2008) (42)
- Head and neck carcinoma in the United States (2012) (42)
- Heat shock stimulates polyamine oxidation by two distinct mechanisms in mammalian cell cultures. (1987) (42)
- Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx. (2012) (42)
- Confirmation of improved local-regional control with altered fractionation in head and neck cancer. (2000) (40)
- Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer (2006) (39)
- Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial. (2016) (39)
- Is radiation dose reduction the right answer for HPV-positive head and neck cancer? (2014) (39)
- Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT). (2014) (38)
- Targeting AKT/PKB to improve treatment outcomes for solid tumors. (2020) (37)
- Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers (2016) (37)
- Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion. (2015) (37)
- IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. (2002) (36)
- Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx (2005) (36)
- Bridging gaps in multidisciplinary head and neck cancer care: nursing coordination and case management. (2007) (35)
- Parotid area lymph node metastases from cutaneous squamous cell carcinoma: Implications for diagnosis, treatment, and prognosis (2005) (35)
- Megavoltage Computed Tomography: An Emerging Tool for Image-Guided Radiotherapy (2007) (34)
- Small Molecule Inhibition of MDM2–p53 Interaction Augments Radiation Response in Human Tumors (2015) (34)
- The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors (2013) (34)
- Tumor Volume as a Prognostic Factor in Oropharyngeal Squamous Cell Carcinoma Treated With Primary Radiotherapy (2008) (34)
- Risk of cerebrovascular events in elderly patients after radiation therapy versus surgery for early-stage glottic cancer. (2013) (33)
- Augmentation of radiation response with the vascular targeting agent ZD6126. (2006) (32)
- ACCO: ASCO core curriculum outline. (2005) (32)
- Cetuximab (Imclone/Merck/Bristol-Myers Squibb). (2002) (31)
- Hidradenomas and a Hidradenocarcinoma of the Scalp Managed Using Mohs Micrographic Surgery and a Multidisciplinary Approach: Case Reports and Review of the Literature (2009) (31)
- Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database. (2016) (31)
- MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents (2018) (30)
- Influence of Computed Tomography on Pretherapeutic Tumor Staging in Head and Neck Cancer Patients (1998) (30)
- Epidermal Growth Factor Receptor Blockade with C 225 Modulates Proliferation , Apoptosis , and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck 1 (1999) (30)
- Human Tumor‐Lymphatic Microfluidic Model Reveals Differential Conditioning of Lymphatic Vessels by Breast Cancer Cells (2020) (30)
- Radiation oncology advances (2008) (29)
- Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial (2016) (29)
- Dose intensification in curative head and neck cancer radiotherapy--linear quadratic analysis and preliminary assessment of clinical results. (1993) (27)
- Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. (2004) (26)
- Prognostic implications of human papillomavirus status for patients with non-oropharyngeal head and neck squamous cell carcinomas (2017) (26)
- The prognostic value of HPV in head and neck cancer patients undergoing postoperative chemoradiotherapy. (2015) (26)
- Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. (2016) (25)
- Intubation granuloma of the larynx: Successful eradication with low‐dose radiotherapy (1991) (25)
- Identification of stable housekeeping genes in response to ionizing radiation in cancer research (2017) (25)
- EGFR-targeting monoclonal antibodies in head and neck cancer. (2006) (25)
- Advances in radiation therapy for head and neck cancer (1995) (24)
- Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers (2015) (24)
- Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models (2015) (23)
- Adding dose escalation to accelerated hyperfractionation for head and neck cancer: 76 Gy in 5 weeks (1992) (23)
- Phase II Randomized Trial of Postoperative Chemoradiation Plus Cetuximab for High-risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234) (2009) (22)
- Improving dose homogeneity in routine head and neck radiotherapy with custom 3-D compensation. (1998) (22)
- Matrix density drives 3D organotypic lymphatic vessel activation in a microfluidic model of the breast tumor microenvironment. (2020) (21)
- Idealized versus realized overall treatment times. (1994) (20)
- Assessing p16 Status of Oropharyngeal Squamous Cell Carcinoma by Combined Assessment of the Number of Cells Stained and the Confluence of p16 Staining: A Validation by Clinical Outcomes (2016) (20)
- Beware the swing and a miss: baseball precautions for conformal radiotherapy. (2008) (20)
- Quantitative evaluation of image segmentation incorporating medical consideration functions. (2015) (19)
- Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies (2015) (19)
- Dosimetric differences in flattened and flattening filter-free beam treatment plans (2016) (19)
- Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment (2002) (19)
- Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx (2017) (19)
- Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition (2017) (18)
- Therapeutic selective neck dissection outcomes (2008) (18)
- Increased Oral Mucositis after IMRT versus Non-IMRT when Combined with Cetuximab and Cisplatin or Docetaxel for Head and Neck Cancer: Preliminary Results of RTOG 0234 (2008) (17)
- Therapeutic combination of radiolabeled CLR1404 with external beam radiation in head and neck cancer model systems. (2015) (17)
- Searching for Reliable Epidermal Growth Factor Receptor Response Predictors (2004) (17)
- Longitudinal oncology registry of head and neck carcinoma (LORHAN®): initial supportive care findings (2009) (17)
- Augmentation of Radiation Response by Motesanib, a Multikinase Inhibitor that Targets Vascular Endothelial Growth Factor Receptors (2010) (17)
- Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma. (2017) (17)
- p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC). (2013) (16)
- Reducing radiotherapy target volume expansion for patients with HPV-associated oropharyngeal cancer. (2019) (16)
- Wound healing following combined radiation and cetuximab therapy in head and neck cancer patients. (2011) (16)
- HPV impacts survival of stage IVC non-oropharyngeal HNSCC cancer patients (2018) (15)
- 986ORANDOMIZED PHASE II STUDY OF MEHD7945A (MEHD) VS CETUXIMAB (CET) IN >= 2ND-LINE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD & NECK (RMSCCHN) PROGRESSIVE ON/AFTER PLATINUM-BASED CHEMOTHERAPY (PTCT). (2014) (15)
- Radiosensitization following EGFR signaling inhibition by erlotinib (Tarceva (2003) (14)
- Precautions in the Use of Intensity-Modulated Radiation Therapy (2005) (14)
- Mucoepidermoid carcinoma in a 10‐year‐old girl (1997) (13)
- Antiproliferative effects of N1,N4-dibenzylputrescine in human and rodent tumor cells. (1998) (13)
- Combining polyamine depletion with radiation therapy for rapidly dividing head and neck tumors: strategies for improved locoregional control. (1994) (13)
- Polyamine biosynthesis inhibitors combined with systemic hyperthermia in cancer therapy. (1990) (12)
- Radiation oncologists can assist head and neck cancer patients with smoking cessation. (1995) (12)
- Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors. (2003) (12)
- Acute Hematologic and Mucosal Toxicities in Head and Neck Cancer Patients Undergoing Chemoradiotherapy: A Comparison of 3D-CRT, IMRT, and Helical Tomotherapy (2013) (12)
- Utilization and outcomes of low dose versus high dose cisplatin in head and neck cancer patients receiving concurrent radiation. (2015) (11)
- Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers (2013) (11)
- Phase II Randomized Trial of Surgery Followed by Chemoradiation Plus Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234) (2007) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Chondroradionecrosis of the larynx: 24‐year University of Wisconsin experience (2017) (11)
- Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database (2017) (11)
- Monoclonal antibody blockade of the epidermal growth factor receptor in cancer therapy. (2001) (11)
- The Relationship of Cetuximab-Induced Rash and Survival in Patients with Head and Neck Cancer Treated with Radiotherapy and Cetuximab (2005) (11)
- Polyamine catabolism in rodent and human cells in culture. (1991) (11)
- Insulin growth factor 1 like receptor (IGF-1R) (2016) (11)
- Effects of diethyldithiocarbamate and endogenous polyamine content on cellular responses to hydrogen peroxide cytotoxicity. (1989) (10)
- Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes, NRG Oncology/RTOG 9501-0234. (2015) (10)
- Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program. (2007) (10)
- Dosimetric Comparison of Real-Time MRI-Guided Tri-Cobalt-60 Versus Linear Accelerator-Based Stereotactic Body Radiation Therapy Lung Cancer Plans (2017) (10)
- COMMENT ON : DISTINGUISHING SECOND PRIMARY TUMORS FROM LUNG METASTASES IN PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA. AUTHORS' REPLY (1998) (10)
- Phase I trial of bevacizumab combined with concurrent chemoradiation for squamous cell carcinoma of the head and neck: Preliminary outcome results. (2011) (10)
- Selective omission of level V nodal coverage for patients with oropharyngeal cancer: Clinical validation of intensity‐modulated radiotherapy experience and dosimetric significance (2016) (9)
- Scanned focussed ultrasound hyperthermia: Clinical response evaluation (1990) (9)
- Primary Head and Neck Tumour-Derived Fibroblasts Promote Lymphangiogenesis in a Lymphatic Organotypic Co-culture Model (2021) (9)
- Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers (2020) (9)
- Gender associations in head and neck squamous cell carcinoma (HNSCC). (2012) (9)
- Head and Neck Cancer (2010) (9)
- Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer (2004) (9)
- Modulation of tumor cell proliferation and apoptosis by polyamine depletion in cells of head and neck squamous cell carcinomas. (1999) (9)
- Impact of HPV Status on the Prognostic Potential of the AJCC Staging System for Larynx Cancer (2018) (8)
- Surgical wound healing in advanced head and neck cancer patients undergoing neck dissection following high dose radiation ± cetuximab (2003) (8)
- Clinical application of EGFR inhibitors in head and neck squamous cell cancer. (2008) (8)
- Modulation of proliferation kinetics in human squamous cell carcinomas of the head and neck. (1993) (8)
- Intensity-modulated radiation therapy in the management of head and neck cancer (2005) (8)
- Functional preservation and quality of life in head and neck radiotherapy (2009) (8)
- Clinical advancement of EGFR inhibitors in cancer therapy. (2006) (8)
- Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas. (2020) (8)
- Nationwide Survey of Patients' Perspectives Regarding Their Radiation and Multidisciplinary Cancer Treatment Experiences. (2019) (7)
- Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216 (2018) (7)
- Re: Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. (1998) (7)
- Augmentation of radiation response with the VEGFR-tyrosine kinase inhibitor ZD6474 (2004) (7)
- Abstract 637: MEHD7945A, an EGFR/ErbB3 dual specific antibody, overcomes acquired resistance to EGFR inhibitors in head and neck and lung tumors (2011) (7)
- Therapeutics , Targets , and Chemical Biology p 53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation (2011) (7)
- Molecular Targeted Therapies in Head and Neck Cancer (2011) (6)
- Incidental Parotid Neoplasms (2015) (6)
- Refining target coverage and normal tissue avoidance with helical tomotherapy vs linac-based IMRT for oropharyngeal cancer (2004) (6)
- EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck (2008) (6)
- Patient and tumor characteristics predictive of primary parotid gland malignancy: A 20-year experience at the University of Wisconsin. (2015) (6)
- Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN), a new national cancer registry. (2007) (6)
- Stepwise progress in epidermal growth factor receptor/radiation studies for head and neck cancer. (2007) (6)
- Intensity-modulated radiation therapy in the management of head and neck cancer. (2005) (6)
- Duration of Mucositis and Dysphagia following Radiotherapy (+ Cetuximab) for Locoregionally Advanced Head and Neck Cancer (2007) (6)
- Outcomes for patients with head and neck squamous cell carcinoma presenting with N3 nodal disease (2017) (6)
- Erratum to: Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab (2016) (6)
- Enhancing the anti-tumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. (2004) (6)
- Multiple daily fractionation radiotherapy schedules in lung cancer (2001) (5)
- 188 Development of conformal avoidance tomotherapy in the treatment of head and neck cancer (1999) (5)
- Anti-EGFR therapy update: clinical experience and adverse event insights. (2006) (5)
- Lymph Node Yield in Therapeutic Neck Dissection: Impact of Dissection Levels and Prior Radiotherapy (2017) (5)
- EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. (2006) (5)
- Emphasizing conformal avoidance versus target definition for IMRT planning in H&N cancer (2003) (5)
- NRG-RTOG 1016: Phase III Trial Comparing Radiation/Cetuximab to Radiation/Cisplatin in HPV-related Cancer of the Oropharynx (2018) (5)
- Slowing proliferation in head and neck tumors: in vitro growth inhibitory effects of the polyamine analog BE-4-4-4-4 in human squamous cell carcinomas. (1995) (5)
- Molecular Target Approaches in Head and Neck Cancer: EGFR and Beyond (2011) (4)
- Clinical outcomes for larynx patients with cancer treated with refinement of high‐dose radiation treatment volumes (2020) (4)
- Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma (2022) (4)
- OC-0211: Real-time MRI-guided Radiotherapy for pancreatic cancer (2016) (4)
- Auriculotemporal Nerve Involvement in Parotid Bed Malignancy (2019) (4)
- Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology. (2016) (4)
- Nodal Metastasis Count and Oncologic Outcomes in Head and Neck Cancer: A Secondary Analysis of NRG/RTOG 9501, NRG/RTOG 0234, and EORTC 22931. (2022) (4)
- 993PDASSOCIATION OF HUMAN PAPILLOMAVIRUS (HPV) AND P16 STATUS WITH EFFICACY AND SAFETY DATA IN THE PHASE III RADIOTHERAPY (RT)/CETUXIMAB (CET) REGISTRATION TRIAL FOR LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (LASCCHN). (2014) (4)
- Establishment of acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in human tumor cell lines (2004) (3)
- Dosimetric and Biologic Differences in Flattened and Flattening-Filter-Free Beam Treatment Plans (2015) (3)
- Panitumumab, a Fully Human Anti-EGFR Monoclonal Antibody, Augments Radiation Response in Xenograft Models of Upper Aerodigestive Tract Cancers (2007) (3)
- Combining Stereotactic Body Radiotherapy and Microwave Ablation Appears Safe and Feasible for Renal Cell Carcinoma in an Early Series. (2021) (3)
- Rapid Access Palliative Radiation Workflow Using MRI-Guided Single-Session Simulation, Online Adaptation, and Treatment (2017) (3)
- Lessons Learned from Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients (2019) (3)
- Is HPV‐Associated Oropharyngeal Cancer Becoming More Common in Older Patients? (2018) (3)
- Modulating radiation response with the histone deacetylase (HDAC) inhibitor SAHA in human carcinomas (2004) (3)
- Pan-HER receptor inhibition augments radiation response in human lung and head and neck cancer models (2015) (3)
- A Comprehensive Assessment by Tumor Site of Patient Setup using Daily MVCT Imaging from Over Three Thousand Eight Hundred Helical Tomotherapy Treatments (2009) (3)
- When Disaster Strikes: Mitigating the Adverse Impact on Head and Neck Cancer Patients. (2018) (3)
- Declining Medical Student Interest in Radiation Oncology - Wake-up Call with a Silver Lining? (2021) (3)
- Erratum to: Insulin-like growth factor 1 receptor mediated tyrosine 845 phosphorylation of epidermal growth factor receptor in the presence of monoclonal antibody cetuximab (2016) (3)
- Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (3)
- MO‐E‐AUD C‐03: Use of FLT‐PET Imaging to Assess Tumor and Normal Tissue Response to Radiotherapy (2008) (3)
- Evaluation and quality control of a commercial 3-D dose compensator system. (1994) (3)
- Why So Challenging to Personalize Radiation Dose? (2017) (2)
- Immunocytokine augments local and abscopal response and animal survival when added to radiation and CTLA-4 checkpoint inhibition in a murine melanoma model (2015) (2)
- Long-Term Update of a Phase II Study of Concurrent Chemoradiotherapy Using Radiation + Bevacizumab (BV) For Locally or Regionally Advanced Nasopharyngeal Cancer (NPC): RTOG 0615 (2020) (2)
- TU-AB-BRA-11: Indications for Online Adaptive Radiotherapy Based On Dosimetric Consequences of Interfractional Pancreas-To-Duodenum Motion in MRI-Guided Pancreatic Radiotherapy. (2016) (2)
- Abstract 1027: EGFR targeting antibody SYM004 causes radiosensitization in tumor cells expressing wild-type K-Ras via modulation of MAPK signaling. (2013) (2)
- Phase I Trial of Bevacizumab followed by Concurrent Radiation, Bevacizumab and Cisplatin for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (2010) (2)
- Abstract 2721: MEHD7945A, dual specific antibody against EGFR and HER3, augments radiation response in head and neck squamous cell carcinoma (2012) (2)
- 1042 Head and neck cancer patient perspectivesregarding pain, cosmesis, swallow function, voice quality and overall quality of life (1996) (2)
- The correlation between the severity of cetuximab-induced rash and clinical outcome for patients with head and neck carcinoma treated with chemoradiotherapy (CRT) plus cetuximab: The RTOG experience. (2014) (2)
- PV-0322: Rapid Early Response of Gastroesophageal Junction Tumors During Real-time MRI-Guided Radiotherapy (2017) (2)
- A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer (2022) (2)
- Personalized Treatment for Lacrimal Sac Adenoid Cystic Carcinoma: Case Report and Literature Review. (2019) (2)
- Treating Advanced Head and Neck Cancer When Cisplatin Is Not an Option. (2020) (2)
- Abstract 2102A: Simultaneous targeting of EGFR and ALK in EML4-ALK positive lung cancer to inhibit tumor cell proliferation and migration (2016) (2)
- Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck cancer from a phase II clinical trial: NRG Oncology RTOG 0234. (2019) (2)
- Refining guidelines regarding unilateral treatment in patients with well-lateralized squamous cell carcinoma of the palatine tonsil and multiple positive nodes or extranodal extension. (2021) (2)
- Targeting HER3-dependent activation of nuclear AKT improves radiotherapy of non-small celllung cancer. (2022) (2)
- Abstract 2720: Sym004, a novel anti-EGFR antibody mixture augments radiation response in human lung and head and neck cancer models (2012) (2)
- 80: Are We Overestimating the Impact of IMRT in Oropharynx Cancer? An Inter-Era Comparison (2006) (2)
- Prospective Study of PET/MRI Tumor Response During Chemoradiotherapy for Patients With Low-risk and Intermediate-risk p16-positive Oropharynx Cancer (2022) (2)
- Evolution in H&N IMRT Practice and Early Assessment of Outcome at a Single Academic Center (2005) (2)
- Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade. (2022) (2)
- P-953 Enhancement of radiation response in upper aero-digestive tracttumors with bevacizumab (Avastine®) (2005) (2)
- O-246 Modulation of radiation response after HER1/EGFR inhibition by erlotinib (Tarceva™) in lung and head and neck carcinoma (2003) (2)
- Abstract 2610: AMG 232, a small molecular inhibitor of MDM2 augments radiation response in human tumors harboring wild-type p53 (2014) (2)
- Robotics in head and neck cancer: future opportunities. (2010) (2)
- Longitudinal oncology registry of head and neck carcinoma (LORHAN): First report of outcomes. (2016) (2)
- Final Report of NRG Oncology RTOG 0022: A Phase I/II Study of Conformal and Intensity Modulated Radiation for Oropharyngeal Cancer. (2021) (2)
- Abstract 4495: Sym013, novel pan-HER monoclonal antibody mixture, augments radiation response in human lung and head and neck tumors (2014) (2)
- Radiation oncology advances: an introduction. (2008) (2)
- PD-036: Association of HPV/p16 status with efficacy and safety in pts with OPC in the phase 3 RT/cetuximab registration trial (2015) (2)
- Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog (2018) (2)
- Assessing Radiation Induced Liver Damage Following MR-Guided Stereotactic Body Radiation Therapy (SBRT): Challenging Current Dose Constraints (2018) (1)
- Abstract 846: Co-targeting of Axl and MerTK improves radiation response in HNSCC (2018) (1)
- PD-144 Tumor response augmentation with combination cetuximab(Erbitux®) and bevacizumab (Avastin®) (2005) (1)
- Inhibition of angiogenesis and metastatic capacity following growth factor receptor blockade combined with radiation (2001) (1)
- Peer review program to enhance treatment planning quality assurance for community radiation oncologists (2020) (1)
- Obituary and Tribute to John "Jack" Francis Fowler, PhD, DSc (1925-2016). (2017) (1)
- Seamless phase II/III trial design with survival and PRO endpoints for treatment selection: Case study of RTOG 1216. (2013) (1)
- Effect of insulin-like growth factor 1 receptor inhibitor on sensitization of head and neck cancer cells to cetuximab and methotrexate. (2009) (1)
- Enhancing Radiation Response in Malignant Gliomas with the Histone Deacetylase (HDAC) Inhibitor LAQ824 (2005) (1)
- Multi-institutional Trial of IMRT for Early Stage Oropharyngeal Cancer: Acceleration via Simultaneously Incorporated Boost (SIB) (RTOG 00-22) (2008) (1)
- Promising New Approaches in the Treatment of Advanced Head and Neck Cancer (2003) (1)
- Why an Increasing Number of Unmatched Residency Positions in Radiation Oncology? A Survey of Fourth-Year Medical Students (2021) (1)
- Longitudinal oncology registry of head and neck carcinoma (LORHAN): Initial treatment findings (2008) (1)
- Metabolic Tumor Volume as a Predictive Imaging Biomarker in Head-and-Neck Cancer: Pilot Results From RTOG 0522 (2013) (1)
- Rates of Malignancy in Incidental and Asymptomatic Parotid Lesions (2014) (1)
- Squamous Cell Carcinomas of the Head and Neck Modulates Proliferation , Apoptosis , and Radiosensitivity in Epidermal Growth Factor Receptor Blockade with C 225 Updated (1999) (1)
- Abstract 2929: Radiosensitization of head and neck cancer by FGFR inhibition (2019) (1)
- Molecular Profiling of Head and Neck Cancer Patient Derived Xenografts Identifies FGFR As a Target for Radiosensitization (2018) (1)
- Potential Influence of ACE Inhibitors and Angiotensin Receptor Blockers on Outcome in Patients With Oropharynx Cancer Treated With Radiation Therapy (2014) (1)
- Abstract A140: MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents (2018) (1)
- Squamous Cell Carcinoma of the Oropharynx: 20-year Outcome Results (2012) (1)
- Adverse Impact of Mucositis on Health Related Quality of Life Outcomes and Resource use in Head and Neck Cancer Patients Receiving Radiation (2007) (1)
- Integrity of Parotid Gland Delineation for H&N IMRT: What Are We Sparing? (2005) (1)
- 345 EGFR therapies with radiation (the head and neck data) (2003) (1)
- Impact of Node Negative Target Volume Delineation on Contralateral Parotid Gland Dose Sparing Using IMRT in Head and Neck Cancer (2015) (1)
- Defining high‐risk elective contralateral neck radiation volumes for oropharynx cancer (2021) (1)
- Immunocytokine Augments the Local and Abscopal Response to Radiation and CTLA4 Checkpoint Inhibition in a Murine Melanoma Model (2015) (1)
- 2820 Association of p16 status and feeding tube use in patients with locoregionally advanced squamous cell cancer of the head and neck treated with radiotherapy +/- cetuximab in a phase III study (2015) (1)
- Methadone Use During Concurrent Chemoradiation in Patients With Head and Neck Cancer (2018) (1)
- Abstract 4013: Transcriptionally mediated effects of radiation on the expression of immune susceptibility markers in murine and human melanoma (2016) (1)
- Abstract 1094: Combining the pan-FGFR inhibitor AZD4547 with radiation in lung and head and neck squamous cell carcinoma (2017) (1)
- The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium. (2007) (1)
- Growth inhibition of squamous cell carcinoma xenografts with the polyamine analogue BE 4444. (1996) (1)
- Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry. (2023) (0)
- Abstract 851: Therapeutic combination of radiolabeled CLR1404 with external beam radiation in head and neck cancer murine xenograft models (2018) (0)
- The Model of an ASTRO Servant Leader. (2021) (0)
- Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx-Reply. (2018) (0)
- Clinical Implications of Scleroderma in the Decision for Radiotherapy-Based Larynx Preservation. (2019) (0)
- I-CLR 1404 tumor dosimetry in xenograft models of head and neck cancer (2022) (0)
- Clinical Outcomes for Larynx Cancer Patients Treated with Refinement of High-Dose Radiation Treatment Volumes (2020) (0)
- Prospective Study of PET/MRI Tumor Response During Chemoradiotherapy for Patients with Low and Intermediate Risk p16-positive Oropharynx Cancers (2022) (0)
- Editorial comment (0)
- Open the Gates for Treatment De-Intensification in Head and Neck Cancer. (2019) (0)
- Mig6 is upregulated in an erlotinib resistant cell line which suppresses EGFR phosphorylation. (2013) (0)
- Long-Term Outcomes for Head and Neck Cancer Patients With N3 Neck Disease (2016) (0)
- Identification of phenocopies improves prediction of targeted therapy response over DNA mutations alone (2022) (0)
- Direct-from-Patient Tumorgrafts of Head-and-Neck Cancers: Preclinical Models for Evaluating Chemoradiation (2012) (0)
- Refining Elective Contralateral Neck Radiation Volumes for Oropharynx Cancer. (2021) (0)
- Patterns of Care and Outcome for N3 Head and Neck Squamous Cell Carcinoma: Review of the National Cancer Data Base (2016) (0)
- 211 Fractionation schedules for cancers of the head and neck (1995) (0)
- Chapter 31 – Oropharyngeal Cancer (2012) (0)
- Feasibility of the Systemic Cure of Cancer With Targeted Radionuclide Therapy (TRT) (2012) (0)
- Increased Pathologic Complete Response to Neoadjuvant Radiation in Rectal Cancer Patients Taking an Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker (2014) (0)
- Applications in Head and Neck Cancer (2006) (0)
- Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN), a new national cancer registry (2006) (0)
- 179 Augmentation of radiation response in upper aero-digestive tract tumors with the vascular targeting agent ZD6126 (2004) (0)
- 2613 : Combined Efficacy of IGF-I Signaling Blockade and Radiation in NSCLC Models (2006) (0)
- Abstract B30: Locoregional control in laryngeal and hypopharyngeal cancer patients treated with radiotherapy using direct gross tumor volume to planning target volume expansion (2020) (0)
- Therapeutic Response to Chemoradiation in HPV-Positive and -Negative HNSCC Cell Lines and Patient-Derived Xenografts (2014) (0)
- Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): First overview of complete data set. (2010) (0)
- Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines (2005) (0)
- Impact of phantom-based partial volume corrections on in vivo dosimetry of theranostic molecularly targeted radionuclide therapy in patient-derived xenograft murine models (2018) (0)
- Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Preliminary Report Regarding Radiation Patterns of Care (2008) (0)
- Abstract 3044: Patient-derived adenoid cystic carcinoma xenografts to study molecular target modulation of tumor radiosensitivity (2016) (0)
- A Soft Spectrum Filter to Improve the Dosimetric and Biologic Aspects of Flattening Filter Free TrueBeam (2015) (0)
- 2124 Improving dose homogeneity in head and neck radiotherapy with custom 3-D compensation (1996) (0)
- Impact of Node Negative (N0) Target Volume on Parotid Gland Dose Sparing in HNSCC (2012) (0)
- Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Findings related to the oropharynx. (2010) (0)
- 2396 : Evolving Treatment Approaches and Outcomes in Oropharynx Cancer: The University of Wisconsin Experience 1990-2005 (2006) (0)
- Head and neck radiotherapy without "hot spots"? Regarding Sohn et al. IJROBP 32:809-813; 1995. (1995) (0)
- Commentary (Harari): Anti-EGFR Therapy Update (2006) (0)
- Effects of diethyldithiocarbamate and endogenous polyamine (2005) (0)
- Head and Neck Cancer of Unknown Primary: Rationale for Selective Administration of Chemotherapy in the Treatment Package (2007) (0)
- Creation of waterproof, TLD probes for dose measurements to validate image-based radiopharmaceutical therapy dosimetry workflow. (2023) (0)
- Errors in Description of Suction Required by Patients. (2018) (0)
- SP-052: Against the Motion (2013) (0)
- PO-125: Primary Radiation-Based Management of Oropharyngeal Cancer: A Comprehensive 20-Year Single Institution Review (2013) (0)
- Post-Radiotherapy Neck Dissection Following Comprehensive H&N IMRT (2005) (0)
- Adjuvant Therapy for Patients with Oral Cavity Cancer (2009) (0)
- SU‐D‐BRC‐06: Multimodality Assessment of Response to Combined Chemoradiation and Anti‐Angiogenic Therapy with CuATSM‐PET, FLT‐PET, and Contrast‐Enhanced CT Imaging (2011) (0)
- Pan-HER Inhibition Induces Radiosensitization in Non-Small Cell Lung (NSCLC) and Head and Neck (HNSCC) Tumor Models (2015) (0)
- 18 Combining EGFR inhibitors with radiation (2009) (0)
- MO-D-204B-08: Classification and Characterization of Tumor Subpopulations Using Molecular Imaging (2010) (0)
- Interstitial Brachytherapy for Lip Cancer: Technical Aspects to Individualize Treatment Approach and Optimize Outcomes. (2023) (0)
- Abstracts of Scientific Papers Presented at the Thirteenth Annual Meeting of the Dysphagia Research Society, Montréal, Quebec, Canada, October 14-16, 2004 (2005) (0)
- Locoregional tumor control in head and neck (H&N) cancer patients following hyperfractionated, accelerated radiotherapy with dose escalation (HARDE) (1994) (0)
- Insulin growth factor 1 like receptor (IGF-1R) (2016) (0)
- Abstract 3309: Co-inhibition of ALK and EGFR and/or c-MET on cell growth and response to radiation in ALK-positive NSCLC cells (2015) (0)
- Abstract IA20: Radiotherapy plus cetuximab or cisplatin in human papilloma-virus positive oropharyngeal cancer (NRG 1016): A randomized multicenter noninferiority trial* (2020) (0)
- Augmentation of Radiation Response by Motesanib, a Multikinase VEGF Receptor Inhibitor (2010) (0)
- High Local Control Rates of p16-Positive Squamous Cell Carcinomas of the Oropharynx Following Intensity Modulated Radiation Therapy Without a Clinical Target Volume Expansion (2018) (0)
- 2132 Diagnosis of occult tonsillar carcinoma in patients with unknown head and neck primary: Impact on radiation field design (1997) (0)
- The Advancement of Epidermal Growth Factor Receptor Inhibitors in Cancer Therapy (2007) (0)
- Manpower issues and training program directions in radiation oncology. (1996) (0)
- Final Report of NRG Oncology RTOG 0022: A Phase I/II Study of Conformal and Intensity. (2023) (0)
- Life Beyond COVID: Pay Attention to Viruses (2020) (0)
- Thursday, November 12, 1992 7:15 – 8:45 a.m.Fractionation in radiation therapy — part I — clinical emphasis, head and neck cancer (1992) (0)
- Overall Treatment Time in the Era of Concurrent Radiochemotherapy for HNSCC: Still Significant for Outcome? (2011) (0)
- In situ vaccination with local radiation and intratumoral immunocytokine to elicit a tumor-specific memory B-cell response. (2017) (0)
- Cancer of the Hypopharynx and Cervical Esophagus (2013) (0)
- Abstract 856: Combination of crizotinib and radiation in the treatment of ALK-positive and cetuximab-resistant lung cancer (2014) (0)
- Can Elective Neck Radiation Treatment Volumes be Safely Reduced to Diminish Toxicity Profiles for Oropharynx Cancer Patients (2017) (0)
- Reducing Radiation Treatment Volumes in the N0 Contralateral Neck for HPV-Positive Oropharynx Patients (2018) (0)
- Patient-Derived Adenoid Cystic Carcinoma Xenografts to Examine Personalized Radiation Therapy (2016) (0)
- TH‐E‐M100J‐05: Early Assessment of Radiotherapy Efficacy with FLT‐PET Imaging (2007) (0)
- Contributions of Targeted Agents (2009) (0)
- Abstract 73: Preclinical evaluation of chemoradiation with cetuximab HPV-positive head and neck cancer suggests significant radiosensitization. (2013) (0)
- Modification of radiation and EGFR inhibitor response in human tumor cells following establishment of radiation resistance (2004) (0)
- Abstract 2630: Inhibition of angiogenesis contributes to enhanced radiation response in tumors following MDM2 inhibition by AMG 232 (2015) (0)
- Chondroradiation Necrosis and Late Radiation-Related Tissue Changes in the Larynx: Twenty-Four–Year University of Wisconsin Experience (2016) (0)
- Conducting a Free Head and Neck Cancer Screening Clinic at a Major Academic Center (2018) (0)
- 6 – Radiotherapy and Chemotherapy (2010) (0)
- 136 INVITED Clinical integration of EGFR inhibitors with radiation (2007) (0)
- Incidence of malignant disease outside the head and neck region in head and neck cancer (2017) (0)
- Head and Neck Simulation study of high-dose-rate brachytherapy for early glottic cancer (2016) (0)
- Clinical Outcomes Using Reduced Target Volume Expansions for Patients with Laryngeal Cancer (2020) (0)
- (OA31) Patterns of Failure for Oral Cavity Squamous Cell Carcinoma Patients Receiving Post-Operative Radiotherapy +/- Chemotherapy (2018) (0)
- Fractionation in radiation therapy - Part II - Radiobiological emphasis (1992) (0)
- Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Analysis of disparities in care. (2011) (0)
- SP-0603: Interaction of radiotherapy with molecular targeting agents (2016) (0)
- Role of Src family kinases in acquired resistance to cetuximab (2007) (0)
- Treatment Outcomes for Advanced Stage Hypopharyngeal Cancer Treated without a GTV to CTV Expansion (2020) (0)
- Abstract 2721: Comparative responses of HPV-positive vs HPV-negative head and neck cancer cells to radiation and/or chemotherapeutic drugs (2011) (0)
- P15 07 MP – ADDING CONTINUOUS ESCALATION TO ACCELERATED HYPERFRACTIONATION FOR HEAD AND NECK CANCER (1991) (0)
- Patient derived adenoid cystic carcinoma xenografts to examine personalized cancer treatment approaches. (2016) (0)
- In response to Drs. Yaes, Bentzen, and Overgaard (1995) (0)
- Impact of HPV-Status on Prognostic Potential of the AJCC Staging System for Larynx Cancer (2018) (0)
- Alterations in EGFR trafficking and degradation in EGFR inhibitor resistant tumor cells (2007) (0)
- Abstract 827: Statistical analyses of stable housekeeping gene expression in cancer post-irradiation (2017) (0)
- Functional Outcomes After Transoral Plus Lateral Pharyngotomy Approach for Advanced Oral and Oropharyngeal Tumors (2023) (0)
- Microphysiological head and neck cancer model identifies novel role of lymphatically secreted monocyte migration inhibitory factor in cancer cell migration and metabolism (2023) (0)
- P-938 Profiling radiation response in EGFR inhibitor-resistant human tumor cells (2005) (0)
- 3:22 pm Response of Endogenous MRI Contrast Metrics (ADC, T2) During Radiotherapy for Prostate Cancer - W. Foltz*, A. Wu, C. Catton, (2010) (0)
- TH-CD-202-11: Implications for Online Adaptive and Non-Adaptive Radiotherapy of Gastic and Gastroesophageal Junction Cancers Using MRI-Guided Radiotherapy. (2016) (0)
- Response to Letter by Dr. Ibott et al. (2010) (0)
- SU‐FF‐J‐135: Quantification of Tumor Proliferation and Hypoxia with PET/CT Imaging of HNSCC Patients Receiving VEGF‐Targeted Therapy (2009) (0)
- Diminishing Toxicity Profiles in Oropharynx Cancer. Can We Safely Spare Nodal Levels IB and V in the Majority of Patients? (2020) (0)
- Targeting nuclear HER3-AKT cascade improves radiotherapy of non-small cell lung cancer (2022) (0)
- Changing Demographics of HPV-Associated Oropharyngeal Squamous Cell Carcinoma (2018) (0)
- Prevalence of Mouth and Throat Soreness (MTS) in Patients undergoing Lung Cancer Treatment, with Adverse Impact on Functional and Quality of Life Outcomes (2008) (0)
- Emphasize Treatment of Known Disease Rather Than Past Footprints. (2020) (0)
- Abstract 2703: Loss of dependence on EGFR signaling by upregulation of Mig6 confers drug resistance to erlotinib (2010) (0)
- Intra-Treatment PET/MRI Separates Intermediate Risk p16-Positive Oropharynx Cancer Patients into Favorable and Unfavorable Cohorts (2020) (0)
- Abstract 4536: Combination external beam and internal radiation via 131I-CLR1404 in the treatment of head and neck squamous cell carcinoma xenografts. (2013) (0)
- Differential Response Rates of Gastrointestinal Tumors During Real-time MRI-Guided Radiation Therapy: Opportunities for Treatment Individualization (2017) (0)
- In vivo synergy of radiation and hu14.18-IL2 immunocytokine results in a memory T cell response in a syngeneic murine melanoma model (2014) (0)
- Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234 (2022) (0)
- 655MO Quality of life in patients with p16+ oropharyngeal cancer receiving accelerated radiotherapy (RT) with either cisplatin or cetuximab in NRG/RTOG 1016 (2022) (0)
- Abstract 4011: Effectivein situimmunization via local radiation therapy (RT) and tumor-specific immunocytokine (IC): Suppression from distant tumor is blocked by RT or Treg-depleting CTLA-4 antibody (2016) (0)
- Molecular and Cellular Pathobiology Enhanced Radiation Sensitivity in HPV-Positive Head and Neck Cancer (2013) (0)
- MO‐D‐204B‐03: Correlation of PET Images of Metabolism, Proliferation and Hypoxia to Characterize Tumor Phenotype in Patients with HNSCC (2010) (0)
- Cervical Lymph Node Metastases from Occult H&N Cancer: Pooled Analysis from the Universities of Florida and Wisconsin Summarizing Patterns of Care and Treatment Outcome (2008) (0)
- S174 – Therapeutic Selective Neck Dissection Outcomes (2008) (0)
- Acquired Resistance to Cetuximab: Rationale for Sequential Therapies Directed Against the EGFR (2007) (0)
- Multi-Institutional Investigation of Relative Pancreatic Tumor to Duodenal Motion in Magnetic Resonance Imaging Guided Radiation Therapy for Potential Online Adaptive Radiation Therapy (2016) (0)
- Treatment Patterns and Outcomes Among Elderly Patients With Locally Advanced Esophageal Cancer: A National Cancer Data Base Analysis (2016) (0)
- Abstract 2356: Establishment of HPV-positive and HPV-negative head and neck cancer tumorgrafts directly from patient biopsies (2012) (0)
- Patterns of failure for hypopharynx cancer patients treated with limited high-dose radiotherapy treatment volumes (2022) (0)
- Relative Prognostic Interplay of HPV Status and PET Scan Maximum Standardized Uptake Value (SUVmax) in Squamous Cell Carcinoma of the Oropharynx (SCC-OP) (2014) (0)
- Interim Report of a Phase II Study of Lapatinib and Concurrent Radiotherapy in Patients With Locally Advanced Head and Neck Cancer (2011) (0)
- TH‐C‐351‐04: 18F‐FLT PET Imaging of Proliferative Response to An EGFR Inhibitor in HNSCC Xenograft Mouse Models (2008) (0)
- Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti‐PDL1 efficacy in head and neck cancer (2023) (0)
- Results From 10 Years of a Free Oral Cancer Screening Clinic at a Major Academic Health Center. (2018) (0)
- Fractionation in radiation therapy - Part I - Clinical emphasis, head and neck cancer (1992) (0)
- T3 Squamous Cell Carcinoma of the Glottic Larynx: Primary Radiation Treatment Outcomes (2016) (0)
- Large Molecule Therapeutics Sym 004 , a Novel Anti-EGFR Antibody Mixture , Augments Radiation Response in Human Lung and Head and Neck Cancers (2013) (0)
- EGFR Signaling and Radiation (2011) (0)
- A Pilot Study of Intra-Treatment MRI/PET to Define Favorable and Unfavorable Radiographic Signatures of Patients with p16-Positive Oropharynx Cancer (2020) (0)
- Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (0)
- International Survey of 4D Dose-Prescriptions in IMRT for Head and Neck Squamous Cell Carcinoma: A Modeled Comparison of Expected Outcome (2005) (0)
- Improved survival of HPV-positive non-oropharyngeal head and neck squamous cell carcinoma (2017) (0)
- Combining H&N IMRT with Weekly Cisplatin Chemotherapy: Early Toxicity and Outcome (2005) (0)
- Combining cytostatic agents with radiation therapy for rapidly dividing head and neck tumors: Strategies for improved locoregional control (1993) (0)
- Development and characterization of EGFR inhibitor resistant lines; A model to study acquired resistance to EGFR blockade (2006) (0)
- Insulin-Like Growth Factor-1 Receptor Signaling Blockade Modulates Cellular Proliferation, Angiogenesis, Xenograft Growth and Radiation-Induced Apoptosis (2005) (0)
- Enhancement of radiation response with bevacizumab (2012) (0)
- Abstract 5474: Epidermal growth factor inhibition of HPV positive head and neck cancer cells and primary tumorgrafts results in significant growth inhibition mediated by apoptosis. (2013) (0)
- Validation of Monte Carlo 131I radiopharmaceutical dosimetry workflow using a 3D‐printed anthropomorphic head and neck phantom (2022) (0)
- Abstract 5187: Potent radiosensitization of adenoid cystic carcinoma in a patient derived xenograft model using the MDM2 inhibitor AMG 232 (2017) (0)
- OC-006: Outcomes of head and neck cancer with N3 nodal disease: a review of the National Cancer Data Base (2017) (0)
- Opiate Use in Patients Undergoing Adjuvant Therapy for Oral Cavity Cancer (2019) (0)
- Abstract A111: The alkyl phosphocholine analog CLR1404 delays radiation-induced dsDNA damage repair in pediatric and adult solid tumors (2018) (0)
- Comprar Radiation Oncology Advances | Mehta, Minesh P. | 9780387367439 | Springer (2007) (0)
- P071) Management and Survival Outcomes for Lymph Node Negative T3 Squamous Cell Carcinoma of the Glottic Larynx (2017) (0)
- Antibody blockade of the epidermal growth factor receptor combined with radiation (2001) (0)
- 31 Rationale for combining EGF receptor blockade with radiation therapy for patients with advanced squamous cell carcinoma of the head and neck (1999) (0)
- Testing Personalized Medicine Using Patient-Derived Xenografts of Head and Neck Cancer (2018) (0)
- Chapter 33 – Oropharyngeal Cancer (2016) (0)
- Human Papillomavirus is Associated With Improved Overall Survival in Patients with Non-oropharyngeal Squamous Cell Carcinomas Presenting With Metastatic Disease (2017) (0)
- Impact of Radiation on Lymph Node Counts and Incidence of Extracapsular-Spread in Neck Dissection Specimens (2013) (0)
- Simulation study of high-dose-rate brachytherapy for early glottic cancer. (2016) (0)
- Treatment for Head and Neck Cancer and for Lung Cancer Causes Significant Diarrhea (2008) (0)
- Real-Time Magnetic Resonance Imaging Guided Radiation Therapy for Gastroesophageal Junction/Gastric Cancers (2016) (0)
- Beyond Cetuximab for Head and Neck Cancer: Dual Target Antibody Blockade of EGFR and HER3 Enhances Radiosensitivity and Overcomes Acquired Resistance to EGFR Inhibitors (2011) (0)
- United States Patterns of Radiation Oncology Practice in the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN) Study (2011) (0)
- Enhanced apoptosis and altered DNA repair underlie improved outcomes in HPV‐positive head and neck cancer (2012) (0)
- Abstract 2352: Molecular profiles of head and neck cancer tumorgrafts (2012) (0)
- Molecular blockade of the EGF receptor combined with radiation in the treatment of head and neck cancer patients: Bench-to-bedside development (2000) (0)
- Abstract 3535: Simultaneous inhibition of Axl and MerTK enhances anti-PDL1 efficacy and creates a pro-inflammatory tumor immune microenvironment in head and neck cancer (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Paul M. Harari?
Paul M. Harari is affiliated with the following schools:
